Selective serotonin reuptake inhibitors and Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Given the failure to develop disease-modifying therapies for Alzheimer's disease (AD), strategies aiming at preventing or delaying the onset of the disease are being prioritized. While the debate regarding whether depression is an etiological risk factor or a prodrome of AD rages on, a key determining factor may be the timing of depression onset in older adults. There is increasing evidence that untreated early-onset depression is a risk factor and that late-onset depression may be a catalyst of cognitive decline. Data from animal studies have shown a beneficial impact of selective serotonin reuptake inhibitors on pathophysiological biomarkers of AD including amyloid burden, tau deposits and neurogenesis. In humans, studies focusing on subjects with a prior history of depression also showed a delay in the onset of AD in those treated with most selective serotonin reuptake inhibitors. Paroxetine, which has strong anticholinergic properties, was associated with increased mortality and mixed effects on amyloid and tau deposits in mice, as well as increased odds of developing AD in humans. Although most of the data regarding selective serotonin reuptake inhibitors is promising, findings should be interpreted cautiously because of notable methodological heterogeneity between studies. There is thus a need to conduct large scale randomized controlled trials with long follow up periods to clarify the dose-effect relationship of specific serotonergic antidepressants on AD prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“But in AD pathology, APP is processed by β-secretase then γ-secretase, yielding Aβ products or senile plaques that accumulate in the extracellular space (O’Brien and Wong, 2011).”
BackgroundOwnby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493 · cited 2×
“However, there is an ongoing debate regarding whether depression is an etiological risk factor (Ownby et al., 2006) or rather a prodrome/early manifestation of AD (Panza et al.”
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556 · cited 1×
“By the third and final stage, the individual ultimately develops AD dementia, which is characterized by cognitive and pathophysiological changes as well as impairment in activities of daily life (Aisen et al., 2017).”
BackgroundDepression as a Risk Factor for Alzheimer Disease: The MIRAGE Study
Green, R. C., Cupples, L. A., Kurz, A., Auerbach, S., Go, R., Sadovnick, D., Duara, R., Kukull, W. A., Chui, H., Edeki, T., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.753 · Cited by 551 · cited 1×
“It has been argued that early-onset depression characterized by a chronic recurring-remitting course with increasing duration and severity of episodes across the lifespan is an etiological risk factor for AD (Green et al., 2003; Gracia-Garcia et al., 2015).”
BackgroundIsmail, Z., for the NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART), Agüera-Ortiz, L., Brodaty, H., Cieslak, A., Cummings, J., Fischer, C. E., Gauthier, S., Geda, Y. E., Herrmann, N., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160979 · Cited by 530 · cited 1×
“…impairment was developed by the International Society to Advance Alzheimer’s Research and Treatment (ISTAART) to increase awareness about later-life onset of neuropsychiatric symptoms including affective and emotional dysregulation as precursors for cognitive decline (Ismail et al., 2017).”
BackgroundCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 6×
“Evidence has been accumulating about the role of serotonin signaling on Aβ and tau proteins accumulation in the brain (Cirrito et al., 2011; Ramos-Rodriguez et al., 2013).”
BackgroundInfluentialThe Value of Delaying Alzheimer’s Disease Onset
Zissimopoulos, J., Crimmins, E., & St.Clair, P. (2015) · Forum for Health Economics and Policy · doi:10.1515/fhep-2014-0013 · Cited by 267
An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223
Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202 · cited 2×
“Interestingly, subjects who received SSRIs for more than 1610 days (defined by the authors as long term use) had a delay of 3 years in conversion to AD compared to subjects who took SSRIs for less than 1610 days: P = 0.008 (Bartels et al., 2018).”
BackgroundInfluentialNELSON, R., GUO, Z., HALAGAPPA, V, PEARSON, M., GRAY, A., MATSUOKA, Y., BROWN, M., MARTIN, B., IYUN, T., & MAUDSLEY, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.037 · Cited by 173 · cited 2×
“There is limited evidence that 5 mg/kg per day of paroxetine may reduce the accumulation of tau proteins (Nelson et al., 2007) and senile plaques (Nelson et al., 2007; Olesen et al., 2017).”
BackgroundHerbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150
Role of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113 · cited 2×
“In their large Danish population-based cohort (Kessing et al., 2009), Kessing and colleagues found that, compared to subjects exposed to one prescription of SSRIs, there was an increased risk of developing AD in subjects exposed to two prescriptions of SSRIs [relative risk (RR) (95% CI) = 1.55…”
BackgroundInfluentialLate-onset major depression: clinical and treatment-response variability
Driscoll, H. C., Basinski, J., Mulsant, B. H., Butters, M. A., Dew, M. A., Houck, P. R., Mazumdar, S., Miller, M. D., Pollock, B. G., Stack, J. A., et al. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1334 · Cited by 57 · cited 1×
“Late-life depression can be either late-onset (defined in most studies as occurring for the first time after the age of 60 years) or early-onset (before the age of 60 years) recurring in later years of life (Driscoll et al., 2005).”
BackgroundWang, J., Zhang, Y., Xu, H., Zhu, S., Wang, H., He, J., Zhang, H., Guo, H., Kong, J., Huang, Q., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140812114715 · Cited by 56
Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study
Heath, L., Gray, S. L., Boudreau, D. M., Thummel, K., Edwards, K. L., Fullerton, S. M., Crane, P. K., & Larson, E. B. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15508 · Cited by 41 · cited 2×
“(Heath et al., 2018).”
Background
Cited by
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Pless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
“Thus, selective serotonin reuptake inhibitors (SSRIs) may have a beneficial role in the pathophysiology of AD [164], ensuring active neuronal signalling is preserved and Aβ and tau fibril deposition are prevented, thereby improving AD.”
Carlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V. A., Kitchen, R. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.012 · Cited by 65
“A number of observational studies have suggested a beneficial effect of serotonin reuptake inhibitor use on cognitive decline (Mdawar et al., 2020), and a small imaging study showed lower levels of key serotonin transporters in MCI (Smith et al., 2017); proteins highlighted in this imaging study…”
Metadata
- Authors
- Khoury, R., Mdawar, B., & Ghossoub, E.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2020
- Volume
- 15
- Issue
- 1
- Pages
- 41
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W2973805821
- Cited by
- 84
- References
- 17
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.